Comparing Revenue Performance: Johnson & Johnson or Travere Therapeutics, Inc.?

Revenue Trends: Johnson & Johnson vs. Travere Therapeutics

__timestamp	Johnson & Johnson	Travere Therapeutics, Inc.
Wednesday, January 1, 2014	74331000000	28203205
Thursday, January 1, 2015	70074000000	99892000
Friday, January 1, 2016	71890000000	133591000
Sunday, January 1, 2017	76450000000	154937000
Monday, January 1, 2018	81581000000	164246000
Tuesday, January 1, 2019	82059000000	175338000
Wednesday, January 1, 2020	82584000000	198321000
Friday, January 1, 2021	78740000000	227490000
Saturday, January 1, 2022	79990000000	212018000
Sunday, January 1, 2023	85159000000	145238000
Monday, January 1, 2024	61350000000

In pursuit of knowledge

A Tale of Two Companies: Revenue Trends from 2014 to 2023

In the world of pharmaceuticals, Johnson & Johnson and Travere Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Johnson & Johnson has consistently demonstrated robust revenue growth, peaking in 2023 with an impressive 15% increase from its 2014 figures. This growth trajectory underscores its dominance in the healthcare sector. In stark contrast, Travere Therapeutics, Inc., a smaller player, has shown a more volatile revenue pattern. Despite a promising 700% increase from 2014 to 2021, its revenue dipped by 36% in 2023. This divergence highlights the challenges faced by emerging biotech firms in maintaining consistent growth. As we delve into these trends, it becomes evident that while size and scale offer stability, innovation and agility are crucial for smaller companies to thrive in a competitive landscape.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025